Celularity Inc (CELU)vsNovartis AG ADR (NVS)
CELU
Celularity Inc
$0.93
-2.68%
HEALTHCARE · Cap: $32.01M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 139330% more annual revenue ($56.58B vs $40.58M). NVS leads profitability with a 23.9% profit margin vs -198.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
CELU
Avoid19
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.7%
Fair Value
$9.22
Current Price
$0.93
$8.29 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -6367.0% — below average capital efficiency
Revenue declined 43.2%
Earnings declined 61.3%
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
CELU has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Return on Equity, Revenue Growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
CELU profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.70 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 19/100), backed by strong 23.9% margins. CELU offers better value entry with a 86.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is an innovative biotechnology company dedicated to pioneering regenerative medicine through its proprietary cellular products derived from the placenta. The firm boasts a robust pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, targeted at improving treatment efficacy and minimizing complications for cancer and other serious diseases. Supported by a seasoned leadership team and strategic collaborations, Celularity is strategically positioned to meet substantial unmet medical needs, thereby establishing itself as a pivotal entity in the dynamic landscape of advanced therapeutics.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?